Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes

ABSTRACT: DNA glycation, a non-enzymatic modification triggered by reactive metabolites such as methylglyoxal (MG), has been implicated in various metabolic and neurological disorders. However, its genome-wide distribution and biological consequences in the developing brain remain largely unexplored. To address this gap, we developed a novel method, GlyDIP-seq, which enables high-resolution profiling of glycation-derived DNA lesions (specifically N²-carboxyethyl-2'-deoxyguanosine, CEdG) across the genome.

ORGANISM(S): Homo sapiens

PROVIDER: GSE296615 | GEO | 2026/05/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [DIP-Seq]

Project description:DNA glycation, a non-enzymatic modification triggered by reactive metabolites such as methylglyoxal (MG), has been implicated in various metabolic and neurological disorders. However, its genome-wide distribution and biological consequences in the developing brain remain largely unexplored. To address this gap, we developed a novel method, GlyDIP-seq, which enables high-resolution profiling of glycation-derived DNA lesions (specifically N²-carboxyethyl-2'-deoxyguanosine, CEdG) across the genome.

2026-05-18 | GSE298780 | GEO

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [ATAC-seq]

2026-05-18 | GSE303270 | GEO

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes

Project description:Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes

| PRJNA1260240 | ENA

Crosstalk between S-nitrosylation and glycation defines a novel metabolic vulnerability in liver and renal cancers

Project description:Methylglyoxal (MGO)-derived advanced glycation end products (AGEs) are hallmarks of carbonyl stress and contribute to cancer progression. Here, we established and validated an LC–MS/MS workflow to detect MGO-induced protein modifications in wild-type (WT) and AKR1A1 knockout (KO) Huh7 cells. Following MGO treatment, proteins were digested and analyzed by liquid chromatography–tandem mass spectrometry to identify characteristic glycation products, including methylglyoxal-derived hydroimidazolone (MG-H1) and Nε-(1-carboxyethyl)-L-lysine (CEL). Comparative analysis demonstrated increased accumulation of MGO-derived modifications in AKR1A1 KO cells compared with WT cells, consistent with impaired detoxification of reactive dicarbonyl species. These findings validate a robust LC–MS/MS workflow for profiling MGO-mediated protein glycation and support its application for investigating carbonyl stress in cancer models.

2026-07-08 | PXD080543 | Pride

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [ATAC-seq]

Project description:Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [ATAC-seq]

| PRJNA1294734 | ENA

Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [DIP-Seq]

Project description:Glycation DNA immunoprecipitation sequencing (GlyDIP-seq) for detecting epigenetic effects unique to diabetes [DIP-Seq]

| PRJNA1271087 | ENA

Methylglyoxal-derived nucleoside adducts drive vascular dysfunction in a RAGE-dependent manner

Project description:Diabetic kidney disease (DKD) is a leading cause of death in patients with diabetes. An early precursor to DKD is endothelial cell dysfunction (ECD), a factor that often precedes and exacerbates vascular disease progression. We previously discovered that covalent adducts formed on DNA, RNA, and proteins by reactive metabolic by-product methylglyoxal (MG) predict DKD risk in patients with type 1 diabetes up to 16 years pre-diagnosis. However, the mechanisms by which MG-adducts contribute to vascular disease onset and progression remain unclear. Here, we report that the most predominant MG-induced nucleoside adducts, N2-(1-carboxyethyl)-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG), drive endothelial dysfunction. Following CEdG or CEG exposure, primary human umbilical vein endothelial cells (HUVECs) undergo endothelial dysfunction, resulting in enhanced monocyte adhesion, increased reactive oxygen species production, endothelial permeability, impaired endothelial homeostasis, and exhibit a dysfunctional transcriptomic signature. These effects were discovered to be mediated through the receptor for advanced glycation end products (RAGE), as an inhibitor for intracellular RAGE signaling diminished these dysfunctional phenotypes. Therefore, we find that not only are MG-adducts biomarkers for DKD, this study reveals they may also have a dual role as potential drivers of vascular disease onset and progression and a new therapeutic modality.

2024-01-19 | GSE251645 | GEO

Dual mechanisms for the antagonistic crosstalk between H3 glycation and H3K4me3 [CUT&Tag]

Project description:Cancer cells undergo profound metabolic reprogramming that elevates the intracellular levels of reactive byproducts such as methylglyoxal (MGO), which can non-enzymatically modify macromolecules in a process known as glycation. Histones are particularly susceptible to glycation, resulting in substantial alterations to chromatin structure and the epigenetic landscape. However, the mechanism by which histone glycation alters epigenetic landscape and impacts specific transcriptional output in vivo has remained unclear due to the lack of high-resolution tools. Here, we utilize adduct-, site-, and target-specific antibodies we developed against histone H3 glycation at arginine 17 (H3R17MG-H1), one of the most abundant histone glycation marks, to perform precise detection and enrichment of this mark. With these, we show that H3 glycation preferentially accumulates in euchromatin and directly crosstalks with a key active transcription-associated mark, H3K4me3, at transcription start sites. Mechanistically, H3 glycation antagonizes global H3K4me3 through dual pathways: by preventing the recruitment of WDR5-containing methyltransferase complexes to glycated H3 and by transcriptionally inducing KDM5 demethylases expression. The combined effects lead to genome-wide depletion of H3K4me3 and reprogramming of cellular transcriptional networks. Our findings reveal a distinct role for histone glycation as a potent modulator of epigenetic landscape and transcriptional output, serving as a direct link between altered metabolism and cell fate.

2026-03-07 | GSE317232 | GEO

Dual mechanisms for the antagonistic crosstalk between H3 glycation and H3K4me3 [RNA-Seq]

2026-03-07 | GSE317229 | GEO

Dual mechanisms for the antagonistic crosstalk between H3 glycation and H3K4me3

Project description:Cancer cells undergo profound metabolic reprogramming that elevates the intracellular levels of reactive byproducts. These include methylglyoxal (MGO), which can non-enzymatically modify macromolecules in a process known as glycation. Histones are particularly susceptible to glycation, resulting in substantial alterations to chromatin structure and the epigenetic landscape. However, the mechanism by which this impacts specific transcriptional outputs has been difficult to interrogate due to the lack of high-resolution tools. Here, we utilize adduct-, site-, and target-specific antibodies we developed against glycated histone H3 arginine 17 (H3R17MG-H1), one of the most abundant histone glycation marks, to determine its chromatin localization. We show that H3R17MG-H1 preferentially accumulates in euchromatin and directly crosstalks with H3K4me3, a key positive mark of activity at transcription start sites. Mechanistically, H3R17MG-H1 antagonizes global H3K4me3 through dual pathways: by preventing the local recruitment of WDR5-containing methyltransferases and by transcriptionally inducing KDM5 demethylases. The combined effects lead to a genome-wide depletion of H3K4me3 and reprogramming of cellular transcriptional networks. Overall, our findings reveal a distinct role for histone glycation as a potent modulator of the epigenetic landscape and transcriptional outputs, serving as a direct link between altered metabolism and epigenetic state.

2026-03-07 | GSE318078 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data